WinstonWınston
Back
Prestige Consumer Healthcare logo

Prestige Consumer Healthcare

PBH
46
Medical - Distribution · Healthcare
Winston Score
46
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Mixed
Growth
Weak
Cash Flow
Exceptional
Stability
Good
Valuation
Strong

Winston Score History

The full picture

Prestige Consumer Healthcare sells over-the-counter health and wellness products that people buy without a prescription. Its brands include Clear Eyes eye drops, Monistat, BC Powder, Chloraseptic, and Dramamine, among others. The company focuses entirely on self-care products sold directly to everyday consumers through drugstores, grocery stores, and mass retailers like Walmart and CVS.

The company makes money by selling branded consumer health products, relying on brand recognition to charge slightly higher prices than generic alternatives. It operates primarily in the United States, with a smaller international presence, and generates roughly $1.1 billion in annual revenue. Its main competitive advantage is owning a portfolio of trusted, well-known brand names that consumers repeatedly buy out of habit — but the key risk is that private-label store brands continue gaining shelf space and price-conscious shoppers trade down, pressuring both sales volume and margins over time.

Politician Trades

3 trades / 12mo

1 Congressional buy and 2 sells on PBH in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades
Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
51.3%
Healthy — 51.3% gross margin
Profit after running costs
Operating Margin
19.8%
Healthy — 19.8% operating margin
Return on the money invested
ROCE
7.4%
Weak — 7.4% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-1.4%
Shrinking sales (-1.4% YoY)
Profit growth
EPS YoY
-16.5%
Earnings shrinking (-16.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
145%
Turns 145% of profit into real cash
Spare cash per sale
FCF Margin
21.3%
Converts sales into free cash efficiently (21.3%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
1.05
Elevated debt (1.05)
Covers its interest
Interest Cover
6.30x
Adequate interest coverage (6.3x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
14.3x
no trend
Attractive valuation — P/E 14.3

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
+4.6
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (14.3 → 9.7)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial